Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249911 | 0.89 | CPB2 (0.38) | SMN1; SMN2CPB2CPB1MME | |
| SCHEMBL5869764 | 0.89 | CPB2 (0.38) | SMN1; SMN2CPB2CPB1MME | |
| SCHEMBL29071840 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL8249067 | 0.89 | CPB2 (0.38) | SMN1; SMN2CPB2CPB1MME | |
| SCHEMBL30087493 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1MMEPOLB | |
| SCHEMBL16750036 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL5832985 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL5833197 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL8248985 | 0.86 | CPB2 (0.39) | CPB2CPB1MME | |
| SCHEMBL5869297 | 0.86 | CPB2 (0.39) | CPB2CPB1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | SMN1; SMN2 3028/4885CPB2 16/4885CPB1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.